![Gérard Tobelem](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Gérard Tobelem
Fondatore presso Dendrogenix SA
Posizioni attive di Gérard Tobelem
Società | Posizione | Inizio | Fine |
---|---|---|---|
Dendrogenix SA
![]() Dendrogenix SA Pharmaceuticals: MajorHealth Technology Dendrogenix SA is a Belgian Belgium-based biotech company founded in 2018 that designs, develops, and brings proprietary molecules called dendrogenins to patients in the fields of hearing loss and neurology. The company is based in Liege, Belgium. Dendrogenins are cholesterol derivatives that stimulate cell differentiation in the immune and nervous system and induce growth of dendrites on dendritic cell and neuron precursors. The company has developed strong know-how in the chemical and biological aspects of dendrogenins. The company was founded by Stéphane Silvente, Gérard Tobelem, and Philippe Lefèbvre, with Stéphane Silvente serving as CEO since 2018. | Direttore/Membro del Consiglio | 01/01/2018 | - |
Fondatore | 01/01/2018 | - |
Storia della carriera di Gérard Tobelem
Precedenti posizioni note di Gérard Tobelem
Società | Posizione | Inizio | Fine |
---|---|---|---|
THERADIAG | Presidente | 29/05/2012 | 31/10/2018 |
Institut Sup Biotech De Paris | Direttore/Membro del Consiglio | - | 01/07/2017 |
Établissement Français du Sang
![]() Établissement Français du Sang BiotechnologyHealth Technology Établissement Français du Sang collects, prepares, qualifies and distributes blood transfusion products. The company is headquartered in Saint-Denis, France. | Amministratore Delegato | 01/04/2009 | - |
Presidente | 01/04/2009 | - | |
Lariboisière Hospital | Corporate Officer/Principal | - | - |
Université Paris Diderot-Paris 7 | Corporate Officer/Principal | - | - |
OSE IMMUNOTHERAPEUTICS | Direttore/Membro del Consiglio | 10/04/2014 | - |
Independent Dir/Board Member | 10/04/2014 | - | |
Louis Dreyfus Foundation | Direttore/Membro del Consiglio | - | - |
Orphan Synergy Europe-Pharma SA
![]() Orphan Synergy Europe-Pharma SA Pharmaceuticals: MajorHealth Technology Orphan Synergy Europe-Pharma SA engages in the development of immunotherapy products against late stage cancer. Its products include Tedopi as treatment for lung cancer and Memopi technology which helps the immune system to eliminate malignant cells. The company was founded by Dominique Costantini and Emile Loria on November 17, 2004 and is headquartered in Paris, France. | Direttore/Membro del Consiglio | 10/04/2014 | - |
Independent Dir/Board Member | 10/04/2014 | - |
Statistiche
Distribuzione geografica
Francia | 9 |
Belgio | 2 |
Posizioni
Director/Board Member | 5 |
Chairman | 2 |
Independent Dir/Board Member | 2 |
Settori
Health Technology | 6 |
Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
OSE IMMUNOTHERAPEUTICS | Health Technology |
Aziende private | 7 |
---|---|
Theradiag SA
![]() Theradiag SA Medical SpecialtiesHealth Technology Theradiag SA engages in the distribution, development, and manufacturing of in vitro diagnostic and theranostics tests. It operates through the following segments: Theranostics and Diagnostics. The Theranostics segment offers solutions for patients treated with anti-tumour necrosis factor alpha. The Diagnostics segment includes products for anti-immunity, genetics, allergy, infectious disease, drug of abuse, other diagnoses, and instrumentation. The company was founded on December 29, 1986 and is headquartered in Croissy-Beaubourg, France. | Health Technology |
Université Paris Diderot-Paris 7 | Consumer Services |
Établissement Français du Sang
![]() Établissement Français du Sang BiotechnologyHealth Technology Établissement Français du Sang collects, prepares, qualifies and distributes blood transfusion products. The company is headquartered in Saint-Denis, France. | Health Technology |
Orphan Synergy Europe-Pharma SA
![]() Orphan Synergy Europe-Pharma SA Pharmaceuticals: MajorHealth Technology Orphan Synergy Europe-Pharma SA engages in the development of immunotherapy products against late stage cancer. Its products include Tedopi as treatment for lung cancer and Memopi technology which helps the immune system to eliminate malignant cells. The company was founded by Dominique Costantini and Emile Loria on November 17, 2004 and is headquartered in Paris, France. | Health Technology |
Louis Dreyfus Foundation | |
Lariboisière Hospital | |
Dendrogenix SA
![]() Dendrogenix SA Pharmaceuticals: MajorHealth Technology Dendrogenix SA is a Belgian Belgium-based biotech company founded in 2018 that designs, develops, and brings proprietary molecules called dendrogenins to patients in the fields of hearing loss and neurology. The company is based in Liege, Belgium. Dendrogenins are cholesterol derivatives that stimulate cell differentiation in the immune and nervous system and induce growth of dendrites on dendritic cell and neuron precursors. The company has developed strong know-how in the chemical and biological aspects of dendrogenins. The company was founded by Stéphane Silvente, Gérard Tobelem, and Philippe Lefèbvre, with Stéphane Silvente serving as CEO since 2018. | Health Technology |
- Borsa valori
- Insiders
- Gérard Tobelem
- Esperienza